Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221178 · ClinicalTrials.gov registry record
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
A clinical trial of Plasma Cell Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 50
- Enrollment target
- 7
- Study locations
NCT04221178 is a study of Plasma Cell Myeloma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 50 participants, below the 207-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (76% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT04221178, a study of Plasma Cell Myeloma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will test whether stopping maintenance therapy in people with multiple myeloma in MRD-negative remission has the same effect on disease control as continuing this therapy. The study will look at whether people currently on maintenance therapy can safely stop this treatment and continue with active surveillance instead while keeping their MRD-negative remission status for at least 1 year.
Conditions Studied
Interventions
- OTHER Cessation of continuous matinenace therapy
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-01-03 |
| Est. Completion | 2027-01-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04221178
The ClinicalTrials.gov registry entry for NCT04221178 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (76% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Cessation of continuous matinenace therapy is the first listed.
NCT04221178 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04221178 about?
NCT04221178 is a clinical study titled "Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission". This study will test whether stopping maintenance therapy in people with multiple myeloma in MRD-negative remission has the same effect on disease control as continuing this therapy. The study will look at whether people currently on maintenance therapy can safely stop this treatment and continue wi...
What is the current status of trial NCT04221178?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2020-01-03. Estimated completion is 2027-01-03.
What conditions does trial NCT04221178 study?
This clinical trial studies the following conditions: Plasma Cell Myeloma.
What interventions are being tested in trial NCT04221178?
The interventions under investigation include: Cessation of continuous matinenace therapy (OTHER).
Who is sponsoring clinical trial NCT04221178?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04221178 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RECRUITING · Phase 3
-
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
RECRUITING · Phase 2
-
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
RECRUITING · Phase 1
-
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RECRUITING · Phase 3
-
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
RECRUITING · NA
-
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.